Maspin的细胞质表达预示着肺鳞状细胞癌患者的预后不良。

Cytoplasmic expression of maspin predicts unfavourable prognosis in patients with squamous cell carcinoma of the lung.

作者信息

Matsuoka Yuki, Takagi Yuzo, Nosaka Kanae, Sakabe Tomohiko, Haruki Tomohiro, Araki Kunio, Taniguchi Yuji, Shiomi Tatsushi, Nakamura Hiroshige, Umekita Yoshihisa

机构信息

Division of Organ Pathology, Department of Pathology, Tottori University, Tottori, Japan.

Division of General Thoracic Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Japan.

出版信息

Histopathology. 2016 Jul;69(1):114-20. doi: 10.1111/his.12921. Epub 2016 Feb 14.

DOI:10.1111/his.12921

PMID:27297724

Abstract

AIMS

Maspin is known to be a tumour suppressor protein, and its prognostic significance in patients with several types of cancer, including lung squamous cell carcinoma (SCC), has been reported. However, its prognostic impact on lung SCC has been controversial. We explored the prognostic value of maspin expression with particular reference to its subcellular localization in patients with lung SCC.

METHODS AND RESULTS

Paraffin-embedded tissue samples from 101 curatively resected patients with lung SCC were analysed immunohistochemically using an antibody for maspin. Maspin positivity was defined as strong expression in only the cytoplasm and observed in 25 patients (24.6%). It correlated significantly with the presence of lymph node metastasis (P = 0.006) and higher pathological stage (P = 0.003). The patients were followed-up for 2-119 months (median: 50 months), and the maspin-positive group had shorter disease-free survival (DFS) and disease-specific survival (DSS) by log-rank test (P = 0.002, P = 0.016, respectively). Multivariate analysis revealed that the status of maspin was the only independent prognostic factor for DFS and DSS (P = 0.017, P = 0.047, respectively).

CONCLUSIONS

Cytoplasmic expression of maspin could be an independent unfavourable prognostic indicator in patients with lung SCC.

摘要

目的

已知乳腺丝抑蛋白是一种肿瘤抑制蛋白，并且其在包括肺鳞状细胞癌（SCC）在内的多种癌症患者中的预后意义已有报道。然而，其对肺SCC的预后影响一直存在争议。我们探讨了乳腺丝抑蛋白表达的预后价值，尤其参考了其在肺SCC患者中的亚细胞定位。

方法与结果

使用抗乳腺丝抑蛋白抗体对101例接受根治性切除的肺SCC患者的石蜡包埋组织样本进行免疫组织化学分析。乳腺丝抑蛋白阳性定义为仅在细胞质中强表达，在25例患者（24.6%）中观察到。它与淋巴结转移的存在（P = 0.006）和更高的病理分期（P = 0.003）显著相关。对患者进行了2至119个月（中位：50个月）的随访，通过对数秩检验，乳腺丝抑蛋白阳性组的无病生存期（DFS）和疾病特异性生存期（DSS）较短（分别为P = 0.002，P = 0.016）。多变量分析显示，乳腺丝抑蛋白状态是DFS和DSS的唯一独立预后因素（分别为P = 0.017，P = 0.047）。